Rezzayo
Rezzayo ingredients
| Active ingredient | Strength |
|---|---|
| Rezafungin | 200 mg/1 |
What Rezzayo is used for
The FDA lists the approved uses on the official label (below). In the EU, rezafungin is approved as Rezzayo for:
Rezzayo is indicated for the treatment of invasive candidiasis in adults. Consideration should be given to official guidance on the appropriate use of antifungal agents.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Rezzayo
- Generic name
- Rezafungin
- Made by
- Melinta Therapeutics, LLC
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- Drug class
- Echinocandin Antifungal
- FDA approval
- New drug application (NDA) NDA217417
- On the US market since
- 2023
Official information
- Rezzayo prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Rezafungin)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rezzayo?
Rezzayo (Rezafungin) is a specialist medicine made by Melinta Therapeutics, LLC, approved by the US FDA.
What are the ingredients of Rezzayo?
Rezzayo contains Rezafungin (200 mg/1).
Is Rezzayo approved in Europe?
The same active substance is approved in the EU as Rezzayo.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA